GeNeuro Phase 2b Multiple Sclerosis Study Recruitment Reaches Halfway Mark Ahead of Schedule
Therapeutic candidate GNbAC1 is first to target potential primary cause of MS Over 130 of 260 patients enrolled Clinical trial design presented during ECTRIMS Congress Primary data read-out confirmed in 4Q20 ...